Pathophysiology of essential hypertension: Role of the pump, the vessel, and the kidney

Seminars in Nephrology

Volumn 22, Issue 1, 2002, Pages 3-16

  Cain, Ashley E ^a   Khalil, Raouf A ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN A RECEPTOR; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROSTACYCLIN; RHO KINASE; THROMBOXANE A2;

BLOOD PRESSURE REGULATION; BLOOD VESSEL FUNCTION; ESSENTIAL HYPERTENSION; HEART FUNCTION; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SALT INTAKE; SMOOTH MUSCLE CONTRACTION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

BLOOD VESSELS; CARDIAC OUTPUT; HEART; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; KIDNEY; VASCULAR RESISTANCE;

EID: 0036141855     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Working under pressure: The vascular endothelium in arterial hypertension
2. Factors contributing to resistant hypertension. Cardiac considerations
3. The role of multiple action agents in hypertension
4. Quantification of the contribution of cardiac and arterial remodeling to hypertension
5. Increased cardiac performance in mild essential hypertension. Left ventricular mechanics
6. Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension
7. Physiological comparison of labile and essential hypertension
8. Relationship between cardiac output and peripheral resistance in borderline hypertension
9. Hemodynamics in hypertension at rest and during exercise
10. Hemodynamic patterns in the natural history of borderline hypertension
11. Cardiac adaptation to increased systemic blood pressure in borderline hypertensive men
12. Hypertensive heart disease: Pathophysiology and clinical and prognostic consequences
13. Relationship between cardiovascular haemodynamics and goals of antihypertensive therapy
14. The role of the autonomic nervous system in hypertension
15. Twenty-year follow-up of hemodynamics in essential hypertension during rest and exercise
16. Essential hypertension in the elderly: Haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels
17. Age, hypertension and hypercholesterolaemia alter endothelium-dependent vascular regulation
18. Endothelial control of vascular tone and growth
19. Endothelium-derived vasoactive substances: Potential role in hypertension, atherosclerosis, and vascular occlusion
20. Endothelial dysfunction in hypertension
21. Endothelium-derived relaxing and contracting factors
22. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
23. Vascular biology. Old-timer makes a comeback
24. NO: The primary EDRF
25. The role of endothelium in human hypertension
26. Agonist-stimulated calcium entry in primary cultures of human cerebral microvascular endothelial cells
27. Relationship between cyclic guanosine 3′,5′-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: Effects of methylene blue and methemoglobin
28. The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation
29. Role of calcium and endothelium in hypertension, cardiovascular disease, and subsequent vascular events
30. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
31. Endothelin receptors and calcium signaling
32. Vascular biology of endothelin
33. Endothelium-dependent control of vascular tone: Effects of age, hypertension and lipids
34. The endothelium of resistance arteries: Physiology and role in hypertension
35. Vascular effects of endothelin-1 in essential hypertension: Relationship with cyclooxygenase-derived endothelium-dependent contracting factors and NO
36. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension
37. Endothelial dysfunction in hypertension
38. Endothelium-dependent responses in hypertension
39. Heterogeneity of endothelial dysfunction in hypertension
40. Defective L-arginine-NO pathway in offspring of essential hypertensive patients
41. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that NO abnormality is not localized to a single signal transduction pathway
42. Endothelium-derived vasoactive factors in hypertension: NO and endothelin
43. Plasma endothelin concentrations in hypertension
44. The endothelium in hypertension: Bystander, target or mediator?
45. The pathogenesis of cardiovascular disease: Role of the endothelium as a target and mediator
46. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension
47. Endothelium-dependent regulation of resistance arteries: Alterations with aging and hypertension
48. Direct electrochemical measurement of nitric oxide in vascular endothelium
49. Endothelium and high blood pressure
50. Effect of increased availability of endothelium-derived NO precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension
51. Role of endothelium-derived NO in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension
52. Endothelial dysfunction in essential hypertension
53. Alterations of nitric oxide synthase expression with aging and hypertension in rats
54. Hypertension in mice lacking the gene for endothelial NO synthase
55. Measures of endothelial function as an endpoint in hypertension?
56. Selective defect in NO synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension
57. In vitro perfusion studies of human resistance artery function in essential hypertension
58. Endothelial dysfunction in hypertension: Fact or fancy?
59. Endothelial dysfunction and hypertensive vasoconstriction
60. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress
61. Increased superoxide anion production in humans: A possible mechanism for the pathogenesis of hypertension
62. Basal NO production is impaired in offspring of patients with essential hypertension
63. Endothelial dysfunction in hypertension
64. Endothelial dysfunction in hypertension. A critical evaluation
65. Impaired endothelial regulation of vascular tone in patients with systemic arterial hypertension
66. Endothelial dysfunction in hypertension
67. Clinical significance of nitric oxide in hypertension
68. Hypertension, the endothelium and the pathogenesis of chronic vascular disease
69. Secondary endothelial dysfunction: Hypertension and heart failure
70. 2+] determines myosin phosphorylation in agonist-stimulated swine arterial smooth muscle
71. Regulation of smooth muscle contractile elements by second messengers
72. Stimulus-specific patterns of intracellular calcium levels in smooth muscle of ferret portal vein
73. Cytoplasmic free calcium, myosin light chain phosphorylation, and force in phasic and tonic smooth muscle
74. +
75. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility
76. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II
77. 2+] sensitivity of myosin phosphorylation in intact swine arterial smooth muscle
78. Change of Ca2+ requirement for myosin phosphorylation by prostaglandin F2 alpha
79. 2+, crossbridge phosphorylation, and contraction
80. Sustained contraction of vascular smooth muscle: Calcium influx or C-kinase activation?
81. Phenylephrine-induced translocation of protein kinase C and shortening of two types of vascular cells of the ferret
82. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
83. Signal transduction by protein kinase C in mammalian cells
84. Phorbol ester-induced contraction of arterial smooth muscle and inhibition of alpha-adrenergic response
85. Intracellular calcium levels in phorbol ester-induced contractions of vascular muscle
86. i
87. Mechanisms of smooth muscle contraction
88. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells
89. 2+-independent isoforms of protein kinase C differentially translocate in smooth muscle
90. Redistribution of protein kinase C isoforms in association with vascular hypertrophy of rat aorta
91. Platelet-derived growth factor and angiotensin II induce different spatial distribution of protein kinase C-alpha and -beta in vascular smooth muscle cells
92. Identification of protein kinase C isoforms in rat mesenteric small arteries and their possible role in agonist-induced contraction
93. Protein kinase C of smooth muscle
94. 2+ entry during coronary artery contraction by vasoactive eicosanoids
95. i threshold for translocation of the alpha-protein kinase C isoform
96. 2+-ATPase activity by caldesmon
97. + current in rabbit vascular myocytes
98. PKC-mediated redistribution of mitogen-activated protein kinase during smooth muscle cell activation
99. Phosphorylation of smooth muscle caldesmon by mitogen-activated protein (MAP) kinase and expression of MAP kinase in differentiated smooth muscle cells
100. Phosphorylation sequences in h-caldesmon from phorbol ester-stimulated canine aortas
101. Arachidonic acid inhibits myosin light chain phosphatase and sensitizes smooth muscle to calcium
102. Identification of calponin as a novel substrate of Rho-kinase
103. An increased calcium sensitivity of mesenteric resistance vessels in young and adult spontaneously hypertensive rats
104. 2+ channels along the arterial tree
105. 2+ entry mechanisms of vasoconstriction in Wistar-Kyoto and spontaneously hypertensive rats
106. The elevation of the cytoplasmic calcium ions in vascular smooth muscle cells in SHR - Measurement of the free calcium ions in single living cells by lasermicrofluorospectrometry
107. i in vascular smooth muscle cells of female rat
108. Biochemical abnormalities of venous plasma membrane fraction isolated from spontaneously hypertensive rats
109. Enhanced vascular reactivity to protein kinase C activators in genetically hypertensive rats
110. Protein kinase C activity in blood vessels from normotensive and spontaneously hypertensive rats
111. 2+-dependent mitogen-activated protein kinase activation in spontaneously hypertensive rat vascular smooth muscle defines a hypertensive signal transduction phenotype
112. Mitogen-activated protein/extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells
113. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
114. Abnormal pressure-natriuresis in hypertension: Role of nitric oxide
115. Angiotensin II regulates vascular smooth muscle cell pH, contraction, and growth via tyrosine kinase-dependent signaling pathways
116. Control of sodium excretion by angiotensin II: Intrarenal mechanisms and blood pressure regulation
117. The renin-angiotensin system and long-term regulation of arterial pressure
118. Angiotensin II binding sites in rat and primate isolated renal tubular basolateral membranes
119. Localization and properties of angiotensin II receptors in rat kidney
120. Differential regulation of angiotensin II and losartan binding sites in glomeruli and mesangial cells
121. Renal mechanisms of angiotensin II-induced hypertension
122. Renal function curve - A key to understanding the pathogenesis of hypertension
123. Remission of hypertension after renal transplantation